Gavin C. Koh, PhD

Executive Director
Generate:Biomedicines
Somerville, Massachusetts, United States

Disclosure(s): AstraZeneca: Stocks/Bonds (Public Company); Generate:Biomedicines: Stocks/Bonds (Private Company); GlaxoSmithKline: Stocks/Bonds (Public Company)

Presentation(s):

• 87 - Machine Learning-Guided Generation of a Potent Combination of Broadly Neutralizing Sarbecovirus Antibodies with a High Barrier to Resistance

  Thursday, October 17, 2024
  10:30 AM – 10:42 AM US PT

• 89 - First-in-human study of a novel half-life extended monoclonal antibody (GB-0669) against SARS-CoV2 and related sarbecoviruses

  Thursday, October 17, 2024
  10:54 AM – 11:06 AM US PT